Integrin Receptor Antagonist [EPC]

87058 reported adverse events

Drugs of this class: NATALIZUMAB NATALIZUMAB-SZTN VEDOLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Integrin Receptor Antagonist [EPC] class:

# Side effect Count
0 FATIGUE 26064
1 OFF LABEL USE 23325
2 MULTIPLE SCLEROSIS RELAPSE 16980
3 DRUG INEFFECTIVE 16937
4 COLITIS ULCERATIVE 15796
5 HEADACHE 14191
6 MALAISE 11845
7 CROHN^S DISEASE 11743
8 DIARRHOEA 11007
9 ASTHENIA 10397
See all common reactions for Integrin Receptor Antagonist [EPC]

Drugs of the Integrin Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THERAPEUTIC REACTION TIME DECREASED 2756 0.9438
1 COLITIS ULCERATIVE 15796 0.3530
2 LOSS OF THERAPEUTIC RESPONSE 1082 0.3391
3 GENERAL SYMPTOM 2418 0.3223
4 POOR VENOUS ACCESS 3165 0.3056
5 LOSS OF CONTROL OF LEGS 1067 0.2813
6 OPPORTUNISTIC INFECTION 508 0.2744
7 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS 504 0.2679
8 MUCOUS STOOLS 1326 0.2674
9 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 2174 0.2634
See all enriched reactions for Integrin Receptor Antagonist [EPC]